PDS Biotechnology (NASDAQ:PDSB) Stock Sees Heavy Call Option Buying

PDS Biotechnology Corporation (NASDAQ:PDSB) was the target of unusually large options trading on Monday. Traders purchased 4,191 call options on the company. This represents an increase of approximately 99% compared to the average daily volume of 2,103 call options.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PDSB shares. Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of PDS Biotechnology in the 2nd quarter worth about $535,000. Renaissance Technologies LLC boosted its stake in PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after purchasing an additional 44,100 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in PDS Biotechnology during the 2nd quarter valued at about $60,000. Finally, Everhart Financial Group Inc. purchased a new stake in PDS Biotechnology during the 3rd quarter valued at about $29,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Stock Up 9.1%

PDSB stock traded up $0.12 on Monday, reaching $1.50. 11,026,501 shares of the company traded hands, compared to its average volume of 8,294,324. PDS Biotechnology has a one year low of $0.20 and a one year high of $1.55. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. The company has a market cap of $84.24 million, a P/E ratio of -2.37 and a beta of 1.17. The firm has a fifty day simple moving average of $0.54 and a 200-day simple moving average of $0.81.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Research analysts anticipate that PDS Biotechnology will post -0.47 earnings per share for the current year.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers.